InterMune (ITMN) Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver
Tweet Send to a Friend
InterMune, Inc. (Nasdaq: ITMN) announced that results from a 14-day Phase 1b clinical study of ITMN-191 (R7227) in combination with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
